January 16, 2021

The Niche

Trusted stem cell blog & resources

Regenerative medicine

3 min read

What to read when there are almost an endless number of stem cell and regenerative medicine pubs? Here are some suggestions including what I would say is a very unusual Nature paper on making egg cells from stem cells. If this could be done safely with human cells all the way to functional eggs, would you consider stem cell-related fertility treatments to be “Regenerative Medicine”? Regenerative medicine and stem cell pubs Reconstitution of the oocyte transcriptional network with transcription factors, Nature. I’d call this …Read More

3 min read

Today’s The Niche recommended weekly reads post includes both primary papers and also a few media pieces. I’m especially interested in the first piece on making more complex embryo-like structures from ES cells. This is a long way from just making embryoid bodies or EBs. At the end of the post I discuss an article that highlighted what seems to be a super-pricey new fee-scheme for open access work and review at Nature Publishing. Artificial embryos, bioengineered thymus Mouse embryonic stem cells self-organize into …Read More

2 min read

Despite the COVID-19 pandemic there are still some research things we can do including data analysis as well as reading new papers and media articles on science, including regenerative medicine. If the weather’s good and you have wi-fi (or you print articles still on paper) you can even do this out in the fresh air and sunshine, if the weather cooperates. Here are some recommended recent science and regenerative medicine reads. At the end I add what might be the worst case of science …Read More

3 min read

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as RMATs. As a result, the RMAT-qualified gene therapies get to go into a speedier lane of FDA oversight. Today’s post is a mix of recommended reads in the regenerative …Read More

3 min read

Stem cell-based Regenerative Medicine has huge power for good in the clinic and at the same time great potential for economic development. Those two things go hand in hand. As I argued in my stem cell book, biotech commercialization of stem cells is not a bad thing, but rather if it is done responsibly it is a good, necessary part of advancing therapies to help patients. From an economic perspective  stem cell-based Regenerative Medicine is a new, exciting brand. Update, now 6 years later, …Read More